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264RanBP3 Regulates Melanoma Cell
Proliferation via Selective Control of
Nuclear Export
Gaurav Pathria1,2, Bhavuk Garg1, Christine Wagner1, Kanika Garg1, Melanie Gschaider1, Ahmad Jalili1
and Stephan N. Wagner1Chromosome region maintenance 1-mediated nucleocytoplasmic transport has been shown as a potential
anticancer target in various malignancies. However, the role of the most characterized chromosome region
maintenance 1 cofactor ran binding protein 3 (RanBP3) in cancer cell biology has never been investigated.
Utilizing a loss-of-function experimental setting in a vast collection of genetically varied melanoma cell lines,
we observed the requirement of RanBP3 in melanoma cell proliferation and survival. Mechanistically, we
suggest the reinstatement of transforming growth factor-b (TGF-b)-Smad2/3-p21Cip1 tumor-suppressor axis as
part of the RanBP3 silencing-associated antiproliferative program. Employing extensive nuclear export
sequence analyses and immunofluorescence-based protein localization studies, we further present evidence
suggesting the requirement of RanBP3 function for the nuclear exit of the weak nuclear export sequence-
harboring extracellular signal-regulated kinase protein, although it is dispensable for general CRM1-medi-
ated nuclear export of strong nuclear export sequence-harboring cargoes. Rendering mechanistic support to
RanBP3 silencing-mediated apoptosis, consequent to extracellular signal-regulated kinase nuclear entrapment,
we observed increased levels of cytoplasmically restricted nonphosphorylated/active proapoptotic Bcl-2-
antagonist of cell death (BAD) protein. Last, we present evidence suggesting the frequently activated mitogen-
activated protein kinase signaling in melanoma as a potential founding basis for a deregulated post-
translational control of RanBP3 activity. Collectively, the presented data suggest RanBP3 as a potential target
for therapeutic intervention in human melanoma.
Journal of Investigative Dermatology (2016) 136, 264-274; doi:10.1038/JID.2015.401INTRODUCTION
MEK-ERK signaling is central to melanoma cell biology
(Flaherty et al., 2012). Even so, the approaches directly tar-
geting this constitutively activated pathway through small
molecule inhibitors have accomplished encouraging initial
clinical responses, their long-term success has been
confounded by an expansive array of acquired resistance
mechanisms (Solit and Rosen, 2014).
Although cellular signaling pathways and the molecular
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(Hanahan and Weinberg, 2011), the altered protein subcel-
lular distribution, especially a cytoplasmic buildup of various
tumor suppressor proteins, has started to emerge as another
significant mechanism in cancer pathogenesis and thera-
peutic resistance (Cagnol and Chambard, 2010; Jiao et al.,
2008; Kau et al., 2004; Turner and Sullivan, 2008). For
example, the aberrant cellular distribution of inhibitory cell
cycle regulators (p53, p21Cip1, and p27Kip1), transcription
factors (FOXO and NF-kB), and tumor suppressors (INI1/
hSNF5 and BRCA1) has been associated with cancer pro-
gression (Kau et al., 2004).
With chromosome region maintenance 1 (CRM1) being
the core component of the nuclear export machinery, a gene
frequently overexpressed in cancer cells (Huang et al.,
2009; van der Watt et al., 2009), including melanoma
(Pathria et al., 2012), and a candidate whose expression is
associated with poor disease prognosis (Noske et al., 2008;
Shen et al., 2009), most nuclear export inhibition strategies
have primarily focused on developing novel CRM1 in-
hibitors (Turner et al., 2014). These efforts have translated
into highly efficacious and relatively non-toxic Selective
Inhibitors of Nuclear Export (SINE) class of CRM1 inhibitors
that have recently made their way into the clinical trials
(Gerecitano, 2014).
Ran binding protein 3 (RanBP3), a protein characterized as
a cofactor for CRM1-mediated nuclear export, has been
shown to be involved in the early steps of CRM1-mediateduthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
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RanGTP, CRM1, and the export cargo. Furthermore, a recent
study reports RanBP3 as a crucial player downstream of the
oncogenic mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-4,5-bisphosphate 3-kinase signaling
pathways, thus possibly linking aberrant oncogenic signaling
with deregulated nuclear export activity (Yoon et al., 2008).
Although the known functionality as a CRM1 cofactor and
the associations with major oncogenic signaling pathways
would argue for a potential role of RanBP3 in cancer biology,
surprisingly, never has this proposition been systematically
investigated. Therefore, in this study we tested the require-
ment of RanBP3 function in melanoma biology and evaluated
its candidacy as a therapeutic target.
RESULTS
RanBP3 is required for melanoma cell proliferation
and survival
To investigate the role of RanBP3 inmelanoma cell biology,we
adopted a loss-of-function approach. RanBP3 silencing uti-
lizing small interfering RNA (siRNAs) suppressed melanoma
cell proliferation (Figure 1a). Furthermore, RanBP3 silencing in
an extended panel of genetically heterogeneous—encom-
passing virtually every major melanoma-associatedmolecular
alteration (mut-BRAF, mut-NRAS, mut-NF-1, mut-/del-
CDKN2A (p16INK4a), mut-/del-PTEN, and mut-TP53;
Supplementary Table S1 online)—melanoma cell lines simi-
larly compromised proliferation (Figure 1b and Supplementary
Figure S1 online). An increase in annexinV and annexinV þ
propidium iodide positive cell fraction on RanBP3 silencing
demonstrated apoptotic induction in all the tested cell lines
(Figure 1c). Further indication of caspase-3 cleavage and pan-
caspase inhibitor-mediated alleviation of cell death corrobo-
rated its apoptotic nature (Supplementary Figure S2a and b
online). Notably, WM983B-BR melanoma cells that are
resistant to BRAF-inhibitor PLX-4032 (cultured in growth me-
dium comprising PLX-4032) also exhibited apoptotic cell
death on RanBP3 silencing (Figure 1d). However, RanBP3
silencing in primary human skin fibroblasts failed to elicit
apoptotic cell death (Figure 1e). Further underscoring the dif-
ferential dependence of melanoma cells on RanBP3 function,
RanBP3 silencing in telomerase reverse transcriptase-immor-
talized (Pmel/hTERT/CDK4(R24C)/p53DD) nontransformed
primary human melanocyte lines genetically engineered to
ectopically express either BRAFV600E (referred to as HMEL-B)
or NRASG12D (referred to as HMEL-N) did not induce signifi-
cant cell death (Supplementary Figure S2c). These results
underscore RanBP3’s requirement in melanoma cell prolifer-
ation and survival, although it is dispensable in a noncan-
cerous setting.
Interestingly, a closer look at MeWo cells depicted
morphological features typical of senescence (Supplementary
Figure S3a online). Loss of light refractivity, enlargement, and
increased vacuolization were observed in a high percentage
of cells. RanBP3 silencing resulted in a high percentage of
cells staining positive for the established senescence marker,
b-galactosidase, and suppression of phospho-retinoblastoma
levels (Supplementary Figure S3b and c).
Altogether, these data suggest RanBP3 as a regulator of
melanoma cell proliferation and survival.RanBP3 negatively modulates the TGF-b-Smad2/3-p21Cip1
growth suppressor axis
RanBP3 has previously been reported as a nuclear export
mediator of Smad2/3 and, thus, a negative modulator of the
TGF-b-regulated p21Cip1/p15INK4b-mediated tumor suppres-
sive program in primary human keratinocytes (Dai et al.,
2009). In line with this report, we also observed the
requirement of RanBP3 function for Smad2/3 nuclear export
in a melanoma setting (Supplementary Figure S4 online).
Consistently, in the melanoma cells, RanBP3 knockdown also
triggered an induction of p21Cip1 levels, an effect that was
further augmented by the presence of TGF-b (Figure 2a).
Interestingly, however, no change in p15INK4b protein levels
was observed (Figure 2a). Furthermore, an increase in the G1
cell cycle fraction (Supplementary Figure S5 online)
supported the increased p21Cip1 and suppressed phospho-
retinoblastoma levels (Supplementary Figure S3c). Impor-
tantly, a concomitant p21Cip1 silencing, partially, yet signifi-
cantly, relieved the antiproliferative action of RanBP3
silencing (Figure 2b and c). Furthermore, transforming
growth-factor receptor pathway inhibition partially overcame
p21Cip1 induction and the antiproliferative activity associated
with RanBP3 silencing (Figure 2d and e).
These data demonstrate a conserved negative association
between RanBP3 and the TGF-b-Smad2/3-p21Cip1 growth
suppressive axis in a transformed cellular context.
RanBP3 and CRM1-mediated nuclear export
Although RanBP3 is frequently referred to as a cofactor for
CRM1-mediated nuclear export, a systematic interrogation of
its requirement in the nuclear exit of established CRM1
substrates has never been undertaken. Furthermore, to gain a
better understanding of the additional mechanisms underly-
ing the antiproliferative and apoptotic outcome associated
with RanBP3 targeting, we undertook a detailed functional
assessment of RanBP3 involvement in the nuclear export of
three (Survivin, p53, and MEK1) previously established
CRM1 substrates (Henderson and Eleftheriou, 2000).
Notably, survivin and p53 were additionally implicated as
the mechanistic basis for CRM1 inhibition-mediated
apoptosis (Pathria et al., 2012). As reported previously
(Pathria et al., 2012), Leptomycin B-mediated CRM1 inhibi-
tion triggered survivin nuclear entrapment (Figure 3a). In
contrast, RanBP3 silencing failed to elicit a change in the
survivin cellular distribution (Figure 3b). As shown previously
(Chan et al., 2010), after its nuclear entrapment, the sup-
pression of survivin levels was evident (Figure 3c), whereas,
consistent with its failure to trigger survivin nuclear entrap-
ment, RanBP3 silencing also failed to mitigate its expression
levels (Figure 3c).
p53 is exported in a CRM1-dependent manner, with CRM1
inhibition triggering its nuclear entrapment (Freedman and
Levine, 1998), overcoming its cytoplasmic proteasomal
degradation, and thus, inducing its protein levels (Figure 3d).
Again, in contrast to CRM1 inhibition, RanBP3 silencing
failed to influence the p53 subcellular distribution or protein
expression levels (Figure 3e). In line with its dispensability for
the nuclear export of survivin and p53, MEK1 nuclear export,
while relying on CRM1 function (Figure 3f), showed indif-
ference to RanBP3 function (Figure 3g).www.jidonline.org 265
Figure 1. RanBP3 is required for melanoma cell proliferation and survival. (a) Upper panel: M14 and MeWo cells were transfected with control small
interfering RNA (Ct.siRNA) or the indicated siRNA-RanBP3 (si-RanBP3#1, si-RanBP3#2, or si-RanBP3#3) for 72 hours followed by immunoblotting for RanBP3.
Lower panel: M14 and MeWo cells were treated as indicated. The increase in the absolute cell number (y-axis) was determined by subtracting the cell number
at the time of seeding from the cell number 96 hours after siRNA transfection. Error bars represent  SD from triplicates. (b) Upper panel: Indicated melanoma
cell lines were treated with Ct.siRNA or si-RanBP3 (#1 or #2) followed by the assessment of RanBP3 levels by immunoblotting. Lower panel: Indicated
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melanoma cell lines were treated with Ct.siRNA or si-RanBP3 (#1 or #2). The increase in the absolute cell number (y-axis) was determined 96 hours after siRNA
transfection. Error bars indicate SD from triplicates. (c) Indicated melanoma cell lines were treated with Ct.siRNA or si-RanBP3 (#1 or #2) for 96 hours
followed by annexinV and propidium iodide (PI) staining. Numbers on the top-right quadrant indicate the proportion of annexinV-positive (early apoptosis) þ
annexinV and PI-positive (late apoptosis) cells. (d) BRAF-i-resistant WM983B-BR cells were treated as indicated followed by annexinV and PI-based apoptotic
assessment. (e) FB2003 and FB1966 fibroblast cell lines were treated as indicated followed by annexinV and PI staining. ***P  0.001, **P  0.01, *P  0.05
(t-test). RanBP3, ran binding protein 3; siRNA, small interfering RNA.
=
Figure 2. RanBP3 regulates TGF-b-
p21Cip1 signaling axis. (a) UACC-62
and MeWo cells were treated as
indicated for 72 hours followed by
the assessment of the p21Cip1 and p15
levels by immunoblotting; 2 ng/ml
of TGF-b was used. (b) UACC-62
and MeWo cells were treated as
indicated for 72 hours followed by
immunoblotting for the assessment of
p21Cip1. (c) UACC-62 and MeWo cells
were treated as indicated for 96 hours.
The y-axis depicts the increase in the
absolute cell number. Error bars
indicate SD from triplicate values.
(d) Immunoblotting for p21Cip1,
phospho(p)-Smad2/3, and Smad2/3
in UACC-62 and MeWo cells on
indicated treatments for 96 hours.
(e) UACC-62 and MeWo cells were
treated as indicated for 96 hours.
The y-axis depicts the increase in
the absolute cell number. Error bars
indicate SD from triplicate values.
The TGF-b inhibitor SB-431542 was
used at a concentration of 5 nM.
TGF-b inhibitor treatment was
initiated 48 hours after siRNA
treatment. ***P  0.001, **P  0.01,
*P  0.05 (t-test). RanBP3, ran binding
protein 3; siRNA, small interfering
RNA; TGF-b, transforming growth
factor-b.
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Figure 3. RanBP3 in CRM1-mediated nuclear export. (a) Left: Immunofluorescence-based staining for survivin in the indicated cell lines on 6 hours’ LMB
(4 nM) treatment. Right: Quantification of survivin cellular distribution. 50 cells were randomly scored and plotted (y-axis) as cell number with predominant
nuclear (N > C), predominant cytoplasmic (C > N), or equal nuclear and cytoplasmic (N ¼ C) survivin distribution. Error bars indicate SD from three random
scorings. Scale bar ¼ 20 mm. (b) Top: Immunofluorescence-based staining for survivin (left panel) in the indicated cell lines on 72 hours’ treatment with
Ct.siRNA or si-RanBP3 (#1 or #2). Nuclear staining with 40,6-diamidino-2-phenylindole (DAPI; middle panel). Overlay of survivin and nuclear stain (right
panel). Bottom: Corresponding quantification. Scale bar ¼ 20 mm. (c) UACC-62 and MeWo cells were transfected with si-CRM1 (left panel) or si-RanBP3#1
(right panel) for 72 hours followed by immunoblotting for survivin. (d) Top: Immunofluorescent staining for p53 in UACC-62 cells on 6 hours of LMB (4 nM)
treatment. Scale bar ¼ 20 mm. Bottom: UACC-62 and Sk-Mel5 cells were transfected with Ct.siRNA or si-CRM1. After 72 hours, p53 levels were assessed by
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RanBP3 in Melanoma Cell ProliferationPreviously, the work of Englmeier et al. (2001) suggested
the requirement of RanBP3 in the CRM1-mediated nuclear
export of the proteins harboring a weak, but not a strong,
nuclear export sequence (NES). Our own studies (Figure 3)
refuting the requirement of RanBP3 in the export of survivin,
p53, and MEK1 further corroborate this suggestion. To
experimentally validate this proposition, we undertook sys-
tematic sequence alignment studies to establish the NES
consensus. Utilizing previously validated (Henderson and
Eleftheriou, 2000) and NetNES1.1-predicted NESs (http://
www.cbs.dtu.dk/services/NetNES/; la Cour et al., 2004), we
first established the common NES consensus. As previously
proposed (Fu et al., 2011), a consensus sequence [LIVFM]-x-
(2,3)-[LIVFM]-x(2,3)-[LIVFM]-x-[LIVFM] with positions 6, 9,
and 11 being predominated by leucine was predicted
(Figure 4a). All the tested CRM1 export cargoes, including the
ones investigated here, readily conformed to this consensus.
Interestingly, however, sequence alignment of putative NESs
from extracellular signal-regulated kinase 1/2 (ERK1/2), as
predicted by NetNES1.1, with the previously established NES
sequences, exhibited a sharp departure from this consensus
(Figure 4b). Notably, the first two hydrophobic residues (po-
sitions 1 and 6) were separated by four amino acids, an
observation lacking in any of the examined NESs. Further-
more, the classic C-terminal consensus ([LIVFM]-x-[LIVFM])
of two hydrophobic residues interrupted by a non-
hydrophobic residue was distorted by the presence of three
consecutive hydrophobic amino acids [LIF]. Based on the
previous suggestion by Englmeier et al. (2001), these analyses
suggested ERK1/2 as a bearer of a weak NES and, thus, po-
tential seeker of RanBP3 cofactor functionality for their
CRM1-mediated nuclear exit (Figure 4c). Indeed, we
observed the requirement of RanBP3 in ERK1/2 nuclear
export (Figure 4d and e). Curiously, two other CRM1 co-
factors (Nup98 and Nxt1) showed complete dispensability
for ERK1/2 nuclear export (Figure 4d and e). Unchanged
ERK1/2 levels refuted possible protein expression changes as
a confounding factor in the immunofluorescence-based
localization studies (Supplementary Figure S6 online).
Furthermore, an interaction between RanBP3 and ERK1/2
that was immune to Leptomycin B suggested a rather direct
mode of interaction (Figure 4f and g). In addition, on
RanBP3 silencing, the induction of c-Fos and Cyclin D1
levels (Supplementary Figure S7 online) that is frequently
associated with nuclear ERK signaling (Lopez-Bergami et al.,
2007) corroborated a heightened ERK nuclear activity and
localization.
BAD is a proapoptotic protein that executes its function in
the cytoplasmic and mitochondrial compartment. Oncogenic
MAPK signaling overcomes this proapoptotic BAD activity
through p90RSK1-mediated site-specific (Ser112) BAD
phosphorylation (Fang et al., 1999). With RanBP3 silencingimmunoblotting. (e) Top: Immunofluorescent staining for p53 (top panel) in UAC
Nuclear staining with TO-PRO (middle panel). Overlay of p53 and nuclear stain (
transfected with Ct.siRNA or si-RanBP3#1 for 72 hours followed by the immuno
staining for MEK1 in the indicated cell lines on 6 hours of LMB (4 nM) treatmen
Immunofluorescent staining for MEK1 (left panel) in the indicated cell lines on 72
DAPI (middle panel). Overlay of MEK1 and nuclear stain (right panel). (g) Bottom
interfering RNA; LMB, Leptomycin B; MEK, MAPK/ERK kinase; RanBP3, ran binrendering significant levels of ERK restricted to the nucleus
and ERK being the sole positive modulator of p90RSK1 ac-
tivity, we predicted a suppression of p(Ser112)-BAD levels on
RanBP3 silencing. Indeed, RanBP3 knockdown caused a
significant downregulation of inhibitory p(Ser112)-BAD
levels (Figure 4h).
Altogether, these data suggest a high degree of RanBP3
dispensability and selectivity in CRM1-mediated nuclear
export. These results, while showing RanBP3 requirement in
ERK nuclear export, also suggest the mechanistic basis for the
apoptotic outcome of RanBP3 ablation through the restora-
tion of proapoptotic dephosphorylated BAD.
MAPK signaling and RanBP3 activity
We analyzed previously generated gene expression data
(GEO Series accession no. GSE8401; Xu et al., 2008) from
melanocytic nevi (n ¼ 9), primary (n ¼ 31), and metastatic
(n ¼ 52) human melanoma tissue samples for RanBP3
expression levels. No significant change in RanBP3 transcript
levels was observed with the disease progression from nevi to
primary and from primary to metastatic stage (Figure 5a). A
recent report demonstrating a critical post-translational con-
trol of RanBP3 activity through its Ser-58 phosphorylation
downstream of ERK and phosphatidylinositol-4,5-bisphos-
phate 3-kinase signaling (Yoon et al., 2008), together with a
frequent constitutive activity of these signaling modules in
melanoma, alluded to a post-translational control of RanBP3
activity in melanoma cells. To test this proposition, we sub-
jected 16 melanoma cell lines to a systematic correlation
between effective p-RanBP3 and p-ERK1/2 levels. While
demonstrating high p-ERK1/2 levels, the majority of cell lines
also showed inherently high p-RanBP3 levels (Supplementary
Figure S8 online). Among the 16 tested melanoma cell lines,
12 exhibited a positive correlation (Pearson correlation r ¼
0.42) between effective p-ERK and p-RanBP3 (Supplementary
Table S2 and Supplemental Materials online), but because of
the limited sample size, it did not reach statistical signifi-
cance (P > 0.05). To functionally evaluate a causal rela-
tionship between MAPK signaling and RanBP3
phosphorylation, we subjected NRAS-mutant Sk-Mel2 and
BRAF-mutant M14 melanoma cells to MEK inhibition.
Notably, two distinct MEK inhibitors (PD98059 and U0126)
that downregulated p-ERK levels also compromised RanBP3
phosphorylation (Figure 5b). Providing further support to this
signaling nexus, a parallel comparison of BRAF inhibitor-
sensitive WM983B and corresponding BRAF inhibitor-
resistant clone WM983B-BR showed, in the latter, elevated
p-RanBP3 levels that were in line with upregulated p-ERK
levels (Figure 5c). Altogether, these results suggested a post-
translational (phosphorylation-based) regulation of RanBP3
in melanoma cells, downstream of constitutively hyperactive
MEK-ERK signaling.C-62 and Sk-Mel5 cells on 72 hours of Ct.siRNA or si-RanBP3#1 treatment.
bottom panel). Scale bar ¼ 20 mm. (e) Bottom: Indicated melanoma cells were
blotting-based assessment of p53 levels. (f) Left: Immunofluorescence-based
t. (f) Right: Corresponding quantification. Scale bar ¼ 20 mm. (g) Top:
hours’ treatment with Ct.siRNA or si-RanBP3 (#1 or #2). Nuclear staining with
: Corresponding quantification. Scale bar ¼ 20 mm. Ct.siRNA, control small
ding protein 3.
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Figure 4. RanBP3 in ERK nuclear export. (a) The sequence logo was produced through http://weblogo.berkeley.edu/logo.cgi, utilizing 17 experimentally
validated and/or NetNES1.1 (http://www.cbs.dtu.dk/services/NetNES/) predicted NESs. The height of each amino acid one-letter abbreviation reflects the
Shannon information content in units of bits. (b) The NES sequence alignment of 17 experimentally validated and/or NetNES1.1 predicted NESs. (c) Left:
Immunofluorescence-based staining for ERK1/2 (left panel) in MeWo cells on 6 hours of LMB (4 nM) treatment. Nuclear staining with DAPI (middle panel).
Overlay of ERK1/2 and nuclear stain (right panel). (c) Right: Corresponding quantification. Scale bar ¼ 20 mm. (d) Top: MeWo cells were treated as indicated for
72 hours followed by the assessment of Nup98 (left), Nxt1 (middle), and RanBP3 (right) levels by immunoblotting. (d) Middle: MeWo cells were treated as
indicated for 72 hours followed by immunofluorescence-based staining of ERK1/2 (top panel). Nuclear staining with DAPI (middle panel). Overlay of ERK1/2
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The illustrated ability of RanBP3 ablation to compromise
melanoma cell proliferation, regardless of the underlying
molecular alterations, could bear major implications from a
therapeutic standpoint. Although RanBP3 targeting exhibited
objective retardation of melanoma cell proliferation and
elicited apoptotic induction, the magnitude of these effects
certainly fell short of the ones achieved on CRM1 targeting
(Pathria et al., 2012). Given the derailment of multiple
cellular pathways consequent to a virtually complete cessa-
tion of nuclear export on CRM1 inhibition, these differences
are understandable (Pathria et al., 2012). Importantly, the
more selective control of nuclear export as executed by
RanBP3, while likely circumventing potential long-term
toxicity issues of CRM1 targeting, could also present effi-
cient combination approaches to heighten the responses
achieved by lone RanBP3 targeting. For example, with the
ability to reinstate a TGF-b signaling-associated anti-
proliferative program, a combination of RanBP3 silencing
and TGF-b could translate into heightened clinical benefit.
Although p53 tumor suppressor function is frequently
impaired through loss-of-function mutations in various can-
cers (Olivier et al., 2010), most melanomas do carry an intact
p53 (Houben et al., 2011). Although melanomas successfully
circumvent some of the p53 cell cycle retarding activities
through gene deletions or inactivating mutations in tumor
suppressor p16INK4A/p14ARF (Chin, 2003; Monzon et al.,
1998), the mechanisms that bypass p21Cip1 tumor suppres-
sor function are far from clear. The presented data showing
the failure of RanBP3 silencing to induce p53 levels, and the
induction of p21Cip1 in mutant/nonfunctional-p53 harboring
MeWo cells, together, refute p53-mediated p21Cip1 regula-
tion in the RanBP3 knockdown setting. These data further
substantiate the negative regulation of the TGF-b-p21Cip1 axis
through RanBP3-mediated Smad2/3 nuclear export (Dai et al.,
2009). This ability to recruit p21Cip1 tumor suppressor function
in the absence of functional p53 could carry important thera-
peutic benefit. Moreover, ERK-activated RanBP3’s ability to
shuttle Smad2/3 out of the nucleus and, thus, potentially sup-
press activated MAPK (oncogene)-mediated p21Cip1 upregu-
lation and the accompanying senescence program could be a
critical step in melanoma cell transformation.
RanBP3 is frequently purported as a CRM1 cofactor.
However, to the best of our knowledge, never has this role
been experimentally evaluated in the general CRM1-
mediated nuclear export. Our data exhibiting absolute
dispensability of RanBP3 in the nuclear export of previously
established proconsensus NES harboring CRM1 cargoes—
MEK, survivin, and p53—weigh into the proposition thatand nuclear stain (bottom panel). (d) Bottom: Corresponding quantification. Scale
72 hours followed by the assessment of RanBP3 levels by immunoblotting. Lower
by immunofluorescent staining of ERK1/2 (top panel). Nuclear staining with DAP
right: Corresponding quantification. Scale bar ¼ 20 mm. (f) RanBP3-bound ERK1/2
ERK1/2 antibody. CRM1 staining was included as a positive control. The anti-mou
cells were treated with methanol 70% (Mock) or LMB (10 nM) for 1 hour. RanBP
detected by an anti-ERK1/2 antibody. The anti-mouse IgG immunoprecipitates in
treated as indicated for 96 hours followed by the assessment of RanBP3 and p(S11
extracellular signal-regulated kinase; ERK1/2, extracellular signal-regulated kina
MAPK/ERK kinase; NES, nuclear export sequence; RanBP3, ran binding proteinRanBP3 cofactor function is dispensable for nuclear export of
the proteins that harbor a strong NES (Englmeier et al., 2001).
Furthermore, our data suggesting RanBP3 requirement in the
nuclear export of a weak NES harboring ERK1/2 further
support this idea. In the wake of a previous study by Adachi
et al. (2000) suggesting the requirement of MEK in ERK nu-
clear export, the observed failure of RanBP3 silencing to
impair MEK nuclear export hints toward the potential exis-
tence of at least two independent pathways of ERK nuclear
export: (a) CRM1-mediated MEK-dependent and (b) RanBP3-
mediated MEK-independent export. Although our pre-
liminary affinity studies would support these two export
models, a previous report by Burack and Shaw (2005)
refuting MEK involvement in CRM1-mediated ERK export
and a later study by Ebner et al. (2007) suggesting CRM1
dispensability in ERK nuclear export, while alluding to the
lack of understanding of ERK export mechanisms, underscore
the need of more comprehensive biochemical studies.
Furthermore, previous studies witnessing CRM1-independent
RanBP3 nuclear export activity (Dai et al., 2009; Hendriksen
et al., 2005) and the need to gain greater insights into the
antiproliferative mechanisms associated with RanBP3
silencing would argue for a more aggressive analysis of the
RanBP3 export repertoire. Interestingly, although a previous
report suggested the requirement of RanBP3 function in the
maintenance of the Ran cellular distribution in HeLa cells
(Yoon et al., 2008), RanBP3 silencing in melanoma cells
failed to perturb the Ran distribution (data not shown). This
ruled out the contribution of potentially altered Ran locali-
zation to RanBP3 knockdown-associated antiproliferative
outcome in melanoma cells.
The field of melanoma therapeutics currently focuses on
developing new approaches to quantitatively ease the flux
through frequently activated MAPK signaling. However, in
the wake of highly disparate and continuously evolving
mechanisms of MAPK signaling reactivation (Solit and Rosen,
2014), achieving robust quantitative abrogation of this
cascade has remained a formidable challenge. Furthermore,
in recent years, there has been a consistent realization and
appreciation of ERK cellular localization as an important
pathogenetic factor, with nuclear ERK signaling and the
depletion of cancer-associated cytoplasmic ERK activity as
antiproliferative mechanisms (Bollag et al., 2010; Cagnol and
Chambard, 2010; Pathria et al., 2012). However, resetting
normal ERK nuclear distribution has posed a significant
mechanistic challenge, with CRM1 targeting being the only
available avenue (Pathria et al., 2012). In light of this infor-
mation, our data showing RanBP3 requirement in ERK nu-
clear export suggest a new approach for counteringbar ¼ 20 mm. (e) Top: UACC-62 and HeLa cells were treated as indicated for
left: UACC-62 and HeLa cells were treated as indicated for 72 hours followed
I (middle panel). Overlay of ERK1/2 and nuclear stain (bottom panel). Lower
was immunoprecipitated with an anti-RanBP3 antibody and detected by anti-
se IgG immunoprecipitates in lane 2 signifies the negative control. (g) MeWo
3-bound ERK1/2 was immunoprecipitated with an anti-RanBP3 antibody and
lanes 3 and 4 signify the negative control. (h) MeWo and UACC-62 cells were
2)-BAD levels by immunoblotting. DAPI, 40,6-diamidino-2-phenylindole; ERK,
se1/2; LMB, Leptomycin B; MAPK, mitogen-activated protein kinase; MEK,
3.
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Figure 5. MAPK signaling regulates RanBP3 activity. (a) Relative mRNA expression levels (y-axis) of RanBP3 in melanocytic nevi (n ¼ 9), primary human
melanoma (n ¼ 31), and human melanoma metastases (n ¼ 52). (b) Sk-Mel2 and M14 cells were treated with MEK inhibitor, PD-98059 (10 mM; left) or U0126
(1 mM; right) for 6 hours followed by the immunoblotting-based assessment of the indicated molecules. (c) BRAF inhibitor-sensitive WM983B melanoma cells
and their BRAF inhibitor-resistant counterpart WM983B-BR were cultured in RPMI þ 10% FCS and RPMI þ 10% FCS þ 1 mM PLX-4032, respectively. At
70% to 80% confluence, the cells were harvested and the lysates were probed for the indicated proteins by immunoblotting. (d) A working model for RanBP3
knockdown-mediated suppression of melanoma cell proliferation and apoptosis. Compromising RanBP3 function blocks Smad2/3 and ERK1/2 nuclear export.
Nuclear retention of Smad2/3 restores transcriptional regulation of p21Cip1 that in turn suppresses melanoma cell proliferation. Depleted ERK1/2 levels in the
cytoplasm relieve the inhibitory phosphorylation of BAD, thus restoring the latter’s proapoptotic activity. ERK1/2, extracellular signal-regulated kinase1/2; FCS,
fetal calf serum; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; ns, nonsignificant (t-test); RanBP3, ran binding protein 3.
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272ERK-associated protumorigenic activities without the con-
straints of its quantitative easing and the associated pathway
reactivation. However, contingent upon RanBP3’s greater
involvement in the nuclear export process, developing more
specific RanBP3-ERK interference strategies could be highly
rewarding. Analyzing recombinant fragments corresponding
to distinct interaction domains of RanBP3 (Lindsay et al.,
2001) in affinity studies and in vitro export assays could
help ascertain the regions of ERK interaction. Subsequent
peptide competition strategies could prove instrumental in
specifically overcoming the RanBP3-ERK interaction.
In conclusion, the findings of this study propose RanBP3 as
a downstream effector of MAPK signaling that selectively
participates in CRM1-mediated nuclear export to regulate
melanoma cell proliferation (Figure 5d). This study provides a
basis for similar interrogations of RanBP3 function in otherJournal of Investigative Dermatology (2016), Volume 136cancers and argues for its further development as melanoma
therapeutics.
MATERIALS AND METHODS
Cell culture and reagents
All cell lines were cultured in RPMI (Invitrogen, Carlsbad, CA),
supplemented with 10% FCS (Invitrogen). Also see Supplemental
Materials online.
Gene expression profiling
Tissue sampling and gene expression profiling were previously
performed using the Affymetrix U133A microarray platform as
described earlier (Xu et al., 2008). The data have been deposited in
the National Center for Biotechnology Information GEO (Clark et al.,
2000) and are accessible through GEO Series accession no.
GSE8401.
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The absolute cell number (final cell count) and the increase in the
absolute cell number (final cell count e starting cell count) were
determined by CASY counter (Roche Innovatis AG, Bielefeld,
Germany).
RNA interference
siRNA transfections were performed employing Lipofectamine 2000
transfection reagent (Invitrogen, Vienna, Austria) per the manufac-
turer’s instructions.
b-Galactosidase assay
The b-galactosidase (senescence) assay was performed using the
Senescence b-Galactosidase Staining Kit (Cell Signaling Technology,
Danvers, MA).
AnnexinV and/or propidium iodide and caspase inhibition
assays
AnnexinV/propidium iodide-based apoptosis detection and quanti-
fication was performed as previously described (Jalili et al., 2011).
For evaluating the effect of pan-caspase inhibitor, melanoma cells
were pretreated with Z-VAD-FMK (40 mM; BD Biosciences,
Schwechat, Austria) for 2 hours followed by treatment with control
siRNA or si-RanBP3#1. 96 hours after siRNA treatment, cells were
analyzed for apoptosis, as described above.
Immunoblotting
Western blotting was performed as previously described (Jalili et al.,
2011). a-Tubulin staining was used as a control for equal sample
loading. See Supplementary Materials for antibodies, densitometry,
and the calculation of the Pearson correlation.
Immunofluorescence
Immunofluorescence studies were performed as described previ-
ously (Pathria et al., 2012). Images were acquired and analyzed
using the Zen 2008 (version 5.0) software on an Axiovert 200 m
inverted microscope (Zeiss, Oberkochen, Germany).
Sequence alignment and sequence logos
The 17 experimentally validated and/or NetNES1.1-predicted (http://
www.cbs.dtu.dk/services/NetNES/; la Cour et al., 2004) NESs were
aligned as described previously (Henderson and Eleftheriou, 2000).
The sequence logo was produced through http://weblogo.berkeley.
edu/logo.cgi, utilizing the 17 experimentally validated and/or
NetNES1.1-predicted NESs. The height of each amino acid one-
letter abbreviation reflects the Shannon information content in
units of bits (Schneider and Stephens, 1990).
Statistical analysis
Graphpad prism software 5.0 (Graphpad, La Jolla, CA; http://www.
graphpad.com) was used to perform statistical analysis by perform-
ing an unpaired t-test.
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